ReviewFrontiers in immunology2025
Effective venetoclax treatment for indolent T-cell lymphoma of the gastrointestinal tract: a case report and literature review.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indolent T-cell lymphoma of the gastrointestinal tract (iTCL-GI) is rare, lacking standardized treatments. We report a successful venetoclax treatment in one patient with indolent T-cell lymphoma of the gastrointestinal tract. A 35-year-old male was admitted due to complaints of anemia and hematochezia. He was diagnosed with iTCL-GI according to histopathology and next-generation sequencing (NGS). He received the first cycle of CHOP-E chemotherapy, but he continued to have intermittent blood in stools. After starting oral Bcl-2 inhibitor venetoclax, the results of peripheral hemogram and the body temperature gradually turned normal, with no symptoms of hematochezia occurring again. In addition, colonoscopy showed improved ulcers in the ascending and transverse colon. Routine blood tests returned to normal without adverse effects. Therefore, venetoclax may represent a potential treatment approach for iTCL-GI. This report might provide clues for the future management of similar cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.